65,437 trials
Breast Cancer
Primary: Number of Participants With Grade 3+ Treatment-related Skin, Fibrosis, and Breast Pain Adverse Events — 1 participants
Pulmonary Arterial Hypertension
Primary: Absolute Change in Right Ventricular Ejection Fraction — 10.4 % RVEF — p=0.028
Asthma
Primary: Percentage of Participants With Asthma Exacerbation — 44.2; 5.8; 19.2; 1.9 percentage of participants — p=<0.0001
Chronic Low Back Pain
Primary: Change in the Numerical Pain Rating Scale — 5.96; 6.12; 6; 1.22 units on a scale
Recurrent Non-small Cell Lung Cancer · Squamous Cell Lung Cancer · Stage III Non-small Cell Lung Cancer
Primary: 6-month Progression Free Survival (PFS) Rate Within the Entire FGFR1 Amplified Group — 0 percentage of participants
Addiction
Primary: Rapid Visual Information Processing — 0.88; 0.89; 0.87; 0.87 Proportion of Participants
Healthy Volunteers
Primary: Donor Postprocedure Platelet Count Following Donation of Single Platelet Product — 60; 60; 0; 0 Participants
Liver Transplant Recipients · Liver Transplantation · Immunosuppression
Primary: Number of Operationally Tolerant Participants — 33 Participants
Cystic Fibrosis
Primary: Change in Sputum Myeloperoxidase (MPO) Level — -0.10; 0.03 log10 (ng/mL) — p=0.460
Clostridium Difficile
Primary: Seroconversion Rate (SCR) on Day 56 — 71.5; 83.0; 59.6; 0.0 percentage of study participants — p=<0.0001
Venous Thromboembolism · Bleeding
Primary: The Number of Participants With Adverse Events Associated With Warfarin Anticoagulation Following Total Hip and Total Knee Replacement — 2; 4 participants
Tonsillitis · Airway Obstruction · Difficulty Swallowing
Primary: Total Pain Medication — 1.7; 2.2 mg
Immunosuppresion · Thrombocytopenia · Pancytopenia
Primary: Hematologic Response — 38; 20; 3 Participants
Chronic Obstructive Pulmonary Disease
Primary: FEV1 AUC0-12 — 1.477; 1.497; 1.443; 1.514 Liter
Schizophrenic Psychoses
Primary: Change in Negative Symptoms of Schizophrenia as Measured on the PANSS — 16.9; 17.2 units on a scale — p=0.50